In a special report – Foundations Fuel Risky Biotech Ventures - about nonprofits investing in biotechnology companies, FierceBiotech interviews LLS Senior Vice President of Research Richard C. Winneker, Ph.D. about our partnership with Celgene, as well as our Therapy Accleration Program.
LLS is partnering with Celgene to identify and fund promising blood cancer research projects. Together we are leveraging our resources to accelerate innovative research to address areas with significant unmet medical need.
“Our history has been about committing a large percentage of our dollars to academic research,” Winneker says in the article. “In order for that work to better translate into assets of interest to the pharmaceutical industry, we created a program through which pharma companies can provide their advice and financial support.”
The article also talks about the role our Therapy Acceleration Program has played as a bridge to guide research projects through obstacles early in the development pipeline, at which point they can be handed off to larger companies willing to make the investment to take the project further.
Other companies featured in the piece include national Multiple Sclerosis Society, Juvenile Diabetes Research Foundation and the Multiple Myeloma Research Foundation. Like LLS, all of these companies see the urgency of forging collaborations with the ultimate goal of getting new and more effective therapies to patients faster.